阅读说明：本技术 痰热清在制备治疗新型冠状病毒肺炎药物中的应用 (Application of phlegm-heat clearing medicine in preparation of medicine for treating novel coronavirus pneumonia ) 是由 张小利 穆竟伟 刘绍勇 杜学航 于 2020-07-13 设计创作，主要内容包括：本发明涉及痰热清在制备治疗新型冠状病毒肺炎药物中的应用。本发明的痰热清在制备治疗新型冠状病毒肺炎药物中的应用可以缩短新型冠状病毒肺炎肺炎患者病毒核酸转阴时间；可以缩短新型冠状病毒肺炎肺炎患者退热时间；可以缩短新型冠状病毒肺炎肺炎患者咳嗽时间；可以改善新型冠状病毒肺炎肺炎患者咳嗽症状；可以提高新型冠状病毒肺炎肺炎患者指氧饱和度。(The invention relates to application of phlegm-heat clearing in preparation of a novel medicine for treating coronavirus pneumonia. The application of the phlegm-heat clearing medicine in preparing the medicine for treating the novel coronavirus pneumonia can shorten the time for turning the virus nucleic acid of a patient with the novel coronavirus pneumonia to negative; can shorten the time of defervescence of the patients with the novel coronavirus pneumonia; the cough time of a patient with the novel coronavirus pneumonia can be shortened; can improve cough symptom of patients with novel coronavirus pneumonia; can improve the finger oxygen saturation of patients with the novel coronavirus pneumonia.)

1. Application of phlegm-heat clearing medicine in preparing medicine for treating coronavirus pneumonia.

2. The use of claim 1, wherein the medicament is in the form of a capsule or an injection.

3. The use of claim 1, wherein the phlegm-heat clearing shortens the time to negative, time to defervesce, time to cough of viral nucleic acid of the novel coronavirus pneumonia patient.

4. The use of claim 1, wherein the phlegm-heat clearing is effective in improving cough symptoms in patients with novel coronavirus pneumonia and increasing oxygen saturation in patients with novel coronavirus pneumonia.

Technical Field

The invention relates to an application of phlegm heat clearing in preparing a medicine for treating novel coronavirus pneumonia.

Background

The novel coronavirus pneumonia infection pneumonia is a new disease, and no targeted vaccine or specific medicine is available, so that the application research of the phlegm-heat clearing medicine consisting of five medicinal materials of scutellaria baicalensis, bear gall powder, goat horn, honeysuckle and fructus forsythiae in preparing the novel coronavirus pneumonia medicine is developed.

Disclosure of Invention

The invention aims to provide the application of phlegm-heat clearing in preparing a novel medicament for treating coronary virus pneumonia aiming at the defects in the prior art.

In order to achieve the purpose, the invention adopts the technical scheme that:

the invention provides application of phlegm-heat clearing in preparation of a novel medicine for treating coronavirus pneumonia.

Preferably, the medicament is in the form of capsules or injection.

Preferably, the phlegm heat clearing shortens the time for turning the viral nucleic acid of the novel coronavirus pneumonia patients to negative, the time for defervescence and the time for cough.

Preferably, the phlegm heat clearing improves cough symptoms of patients with the novel coronavirus pneumonia and improves oxygen saturation of the patients with the novel coronavirus pneumonia.

By adopting the technical scheme, compared with the prior art, the invention has the following technical effects:

the application of the phlegm-heat clearing medicine in preparing the medicine for treating the novel coronavirus pneumonia can shorten the time for turning the virus nucleic acid of a patient with the novel coronavirus pneumonia to negative; can shorten the time of defervescence of the patients with the novel coronavirus pneumonia; the cough time of a patient with the novel coronavirus pneumonia can be shortened; can improve cough symptom of patients with novel coronary virus pneumonia; can improve the finger oxygen saturation of patients with the novel coronavirus pneumonia.

Drawings

FIG. 1 is a plot of viral nucleic acid negative going time;

FIG. 2 is a graph of the annealing time;

FIG. 3 is a curve of disappearance time of cough symptoms;

FIG. 4 is a PPI network of protein targets associated with the TAN capsule;

FIG. 5 is a PPI network diagram of Cluster module of the protein target spot related to the Tanreqing capsule;

FIG. 6 is GO enrichment analysis of the phlegm-heat clearing capsule associated protein target;

FIG. 7 shows the first 20 pathways of a KEGG pathway enrichment analysis of a protein target related to the Tanreqing Capsule;

FIG. 8 is a network diagram of "Compound-target-pathway-pharmacological action-Effect" of Tanreqing Capsule;

FIG. 9 is a network diagram of components-target points of the phlegm-heat-clearing injection;

FIG. 10 is a PPI network diagram of a target associated with the TARTAIQING injection;

FIG. 11 shows the core target of the phlegm-heat-clearing injection;

FIG. 12 is GO bioprocess analysis;

figure 13 is a KEGG signal pathway enrichment analysis.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without inventive exercise, are within the scope of the present invention.

It should be noted that the embodiments and features of the embodiments may be combined with each other without conflict.

The invention is further described with reference to the following figures and specific examples, which are not intended to be limiting.